Axsome Therapeutics, Inc. (AXSM)

68.92 +0.71 (+1.03%) As of 03:55PM EDT. Market open.

Axsome Therapeutics, Inc.

One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 545

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Herriot Tabuteau M.D.	Founder, Chairman, CEO & President	1.32M	N/A	1968
Mr. Nick Pizzie CPA, M.B.A.	Chief Financial Officer	732.94k	N/A	1975
Mr. Mark L. Jacobson	COO & Secretary	784.66k	N/A	1983
Mr. Hunter Murdock Esq.	General Counsel & Secretary	735.39k	N/A	1980
Dr. Amanda Jones Pharm.D.	Senior Vice President of Clinical Development	N/A	N/A	1983
Ms. Lori Englebert M.B.A.	Executive Vice President of Commercial & Business Development	N/A	N/A	1978
Joseph Debrah-Afful CPA, M.B.A.	Director of Finance	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corporate governance

Axsome Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.